An interventional study of ALRITE in Pneumonia Childhood, Childhood Asthma and Acute Lower Respiratory Illness, sponsored by University of Washington. Not yet recruiting at 1 site in Uganda. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by University of Washington · Not applicable, Interventional, and Health services research
The goal of this study is to pilot test the feasibility of a mobile health clinical decision support tool called ALRITE for the diagnosis and management of acute lower respiratory illnesses in young children in Uganda. Asthma/wheezing illness, in particular, is underdiagnosed in this setting. The main questions the study aims to answer are:
Researchers will compare outcomes before and after ALRITE deployment to healthcare workers at 4 Ugandan healthcare centers using an interrupted time series design. Study participants are healthcare workers.
There will be12 months of baseline data collection ("baseline period"), at the beginning of which healthcare workers will be enrolled at each site. Following the baseline period, health workers will receive ALRITE training and will be encouraged but not required to use ALRITE in clinical care for a 6-month intervention period. Health worker participants will fill out surveys and participate in focus group discussions to provide feedback.
University of Washington is the lead sponsor of 1,397 studies on the registry; 225 are open to participants now.
Of its 154 completed or terminated interventional studies of FDA-regulated products, 132 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Healthcare workers will undergo training in the mobile health decision support tool called ALRITE. They will each receive an ALRITE-enabled tablet to use in clinical care. ALRITE use is encouraged but not required. Researchers will collect clinical data from the health record at each study site to evaluate the effect of the ALRITE intervention on acute lower respiratory illness diagnosis and treatment.
Other: ALRITE
ALRITE is a point-of-care mobile health clinical decision support tool designed for use by healthcare workers in Uganda. ALRITE guides the user into entering patient information and provides guideline-concordant recommendations. ALRITE also includes educational videos and weight-based dosing.
Healthcare worker enrollment (study feasibility)
Number of healthcare workers enrolled during the baseline phase and additional healthcare workers who were enrolled during the remaining study period (ex: new hires or transfers)
Time frame: At enrollment
Healthcare worker retention (study feasibility)
Proportion of healthcare workers active in the study over total number enrolled
Time frame: From enrollment through study completion, an average of 20 months
Availability of ALRITE-enabled devices (study feasibility)
Proportion of functional devices over number of devices provided to the facility per month
Time frame: Monthly during the intervention period from ALRITE deployment through study completion, an average of 6 months
ALRITE training completion (study feasibility)
Number of ALRITE training sessions completed per site
Time frame: During ALRITE deployment at the end of the baseline period, estimated 1-2 months
Data completeness (study feasibility)
Percentage of eligible pediatric cases correctly abstracted from the health facility records into the electronic database.
Time frame: Monthly from baseline (day 1) through the study completion, estimated 20 months
Diagnosis rate of wheezing illness
Diagnosis rates of wheezing illness/asthma among all young children presenting to study sites, as recorded in the health record
Time frame: Monthly from baseline through study completion, estimated 20 months
Diagnosis rate of pneumonia
Diagnosis rates of pneumonia among all young children presenting to study sites, as recorded in the health record
Time frame: Monthly from baseline through study completion, estimated 20 months
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Washington